Published in Microb Pathog on March 24, 2009
Toll-like receptor 5 stimulation protects mice from acute Clostridium difficile colitis. Infect Immun (2011) 1.53
Antibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin A. Infect Immun (2009) 1.21
The enterotoxicity of Clostridium difficile toxins. Toxins (Basel) (2010) 1.07
The antimicrobial peptide cathelicidin modulates Clostridium difficile-associated colitis and toxin A-mediated enteritis in mice. Gut (2012) 1.02
Recurrent Clostridium difficile infection: From colonization to cure. Anaerobe (2015) 1.00
The host immune response to Clostridium difficile infection. Ther Adv Infect Dis (2013) 0.96
Immune responses to Clostridium difficile infection. Trends Mol Med (2012) 0.95
A segment of 97 amino acids within the translocation domain of Clostridium difficile toxin B is essential for toxicity. PLoS One (2013) 0.93
Accelerated neuronal cell recovery from Botulinum neurotoxin intoxication by targeted ubiquitination. PLoS One (2011) 0.90
The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection. Mol Immunol (2014) 0.81
The role of Gr-1(+) cells and tumour necrosis factor-α signalling during Clostridium difficile colitis in mice. Immunology (2015) 0.80
Caspase activation as a versatile assay platform for detection of cytotoxic bacterial toxins. J Clin Microbiol (2013) 0.78
The Role of Rho GTPases in Toxicity of Clostridium difficile Toxins. Toxins (Basel) (2015) 0.77
Utility of Clostridium difficile toxin B for inducing anti-tumor immunity. PLoS One (2014) 0.76
Glucosylation Drives the Innate Inflammatory Response to Clostridium difficile Toxin A. Infect Immun (2016) 0.75
Analysis of TcdB Proteins within the Hypervirulent Clade 2 Reveals an Impact of RhoA Glucosylation on Clostridium difficile Proinflammatory Activities. Infect Immun (2016) 0.75
Clostridium difficile toxin B intoxicated mouse colonic epithelial CT26 cells stimulate the activation of dendritic cells. Pathog Dis (2015) 0.75
Rho GTPases and the actin cytoskeleton. Science (1998) 28.19
Clostridium difficile colitis. N Engl J Med (1994) 9.31
Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun (1982) 6.88
Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature (1995) 6.08
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
Biological activities of toxins A and B of Clostridium difficile. Infect Immun (1982) 4.62
Clostridium difficile--associated diarrhea. Clin Infect Dis (1998) 4.06
Pseudomembranous colitis. J Clin Pathol (1977) 3.93
Clostridium difficile infection. Annu Rev Med (1998) 3.63
Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis (2008) 3.50
The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J Biol Chem (1995) 3.02
Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest (1995) 2.91
Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Infect Immun (1986) 2.89
Effects of cytochalasin D and latrunculin B on mechanical properties of cells. J Cell Sci (2001) 2.74
Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest (1994) 2.25
Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends Microbiol (2008) 2.25
Large clostridial cytotoxins. Rev Physiol Biochem Pharmacol (2004) 2.00
Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology (2003) 1.91
Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol (2008) 1.89
Cytokine response by human monocytes to Clostridium difficile toxin A and toxin B. Infect Immun (1991) 1.87
Bacillus megaterium--from simple soil bacterium to industrial protein production host. Appl Microbiol Biotechnol (2007) 1.85
Localization of the glucosyltransferase activity of Clostridium difficile toxin B to the N-terminal part of the holotoxin. J Biol Chem (1997) 1.83
Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis (2008) 1.76
The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis (2007) 1.66
Purification of Clostridium difficile toxin A by affinity chromatography on immobilized thyroglobulin. Infect Immun (1987) 1.57
Cytoplasmic transport of Stat3 by receptor-mediated endocytosis. EMBO J (2002) 1.43
Tristetraprolin regulates TNF TNF-alpha mRNA stability via a proteasome dependent mechanism involving the combined action of the ERK and p38 pathways. Mol Immunol (2007) 1.43
Activation of TNF-alpha transcription utilizes distinct MAP kinase pathways in different macrophage populations. J Leukoc Biol (2000) 1.40
Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology (2007) 1.35
gp96 is a human colonocyte plasma membrane binding protein for Clostridium difficile toxin A. Infect Immun (2008) 1.30
Comparative study of Clostridium difficile toxin A and cholera toxin in rabbit ileum. Gastroenterology (1989) 1.30
Disruption of the actin cytoskeleton results in nuclear factor-kappaB activation and inflammatory mediator production in cultured human intestinal epithelial cells. J Cell Physiol (2004) 1.28
Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A. J Clin Invest (1996) 1.26
Cellular stability of Rho-GTPases glucosylated by Clostridium difficile toxin B. FEBS Lett (2006) 1.22
Roles of intracellular calcium and NF-kappa B in the Clostridium difficile toxin A-induced up-regulation and secretion of IL-8 from human monocytes. J Immunol (1999) 1.21
Cellular internalisation of Clostridium difficile toxin A. Microb Pathog (1987) 1.20
IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. Am J Physiol (1997) 1.20
Clostridium difficile colitis and diarrhea. Gastroenterol Clin North Am (1993) 1.19
Chimeric clostridial cytotoxins: identification of the N-terminal region involved in protein substrate recognition. Infect Immun (1998) 1.14
Emerging toxin A-B+ variant strain of Clostridium difficile responsible for pseudomembranous colitis at a tertiary care hospital in Korea. Diagn Microbiol Infect Dis (2007) 1.08
Clostridium difficile toxin A induces the release of neutrophil chemotactic factors from rat peritoneal macrophages: role of interleukin-1beta, tumor necrosis factor alpha, and leukotrienes. Infect Immun (1997) 1.07
Application of mutated Clostridium difficile toxin A for determination of glucosyltransferase-dependent effects. Infect Immun (2006) 1.06
Differential expression and polarized secretion of CXC and CC chemokines by human intestinal epithelial cancer cell lines in response to Clostridium difficile toxin A. Microbiol Immunol (2002) 1.04
Clostridium difficile toxin A-induced apoptosis is p53-independent but depends on glucosylation of Rho GTPases. Apoptosis (2007) 0.99
A Bacillus megaterium plasmid system for the production, export, and one-step purification of affinity-tagged heterologous levansucrase from growth medium. Appl Environ Microbiol (2006) 0.99
Clostridium difficile toxin B activates the EGF receptor and the ERK/MAP kinase pathway in human colonocytes. Gastroenterology (2005) 0.97
Clostridium difficile toxins A and B directly stimulate human mast cells. Infect Immun (2007) 0.97
The distribution and density of Clostridium difficile toxin receptors on the intestinal mucosa of neonatal pigs. Vet Pathol (2007) 0.94
Human intestinal epithelial and smooth muscle cells are potent producers of IL-6. Mediators Inflamm (2003) 0.94
The actin cytoskeleton: an essential component for enhanced TNFalpha production by adherent monocytes. Shock (2002) 0.94
Reduction of tumor necrosis factor-alpha (TNF-alpha) related nuclear factor-kappaB (NF-kappaB) translocation but not inhibitor kappa-B (Ikappa-B)-degradation by Rho protein inhibition in human endothelial cells. Biochem Pharmacol (2002) 0.89
The involvement of macrophage-derived tumour necrosis factor and lipoxygenase products on the neutrophil recruitment induced by Clostridium difficile toxin B. Immunology (1997) 0.87
Role of tumor necrosis factor and nitric oxide in the cytotoxic effects of Clostridium difficile toxin A and toxin B on macrophages. Toxicon (1997) 0.86
Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant. Infect Immun (2004) 0.85
Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice. Infect Immun (2000) 0.85
Fc receptor-mediated, antibody-dependent enhancement of bacteriophage lambda-mediated gene transfer in mammalian cells. Virology (2008) 0.84
Actin plays a crucial role in the phagocytosis and biological response to respirable quartz particles in macrophages. Arch Toxicol (2007) 0.84
Comparison of wild type with recombinant Clostridium difficile toxin A. Microb Pathog (2005) 0.84
C-terminal repeats of Clostridium difficile toxin A induce production of chemokine and adhesion molecules in endothelial cells and promote migration of leukocytes. Infect Immun (2007) 0.81
Role of clathrin-mediated endocytosis of surfactant protein A by alveolar macrophages in intracellular signaling. Am J Physiol Lung Cell Mol Physiol (2009) 0.79
Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science (2004) 5.64
The genome of Cryptosporidium hominis. Nature (2004) 3.93
Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis (2011) 1.98
Cryptosporidiosis and microsporidiosis in ugandan children with persistent diarrhea with and without concurrent infection with the human immunodeficiency virus. Am J Trop Med Hyg (2005) 1.90
Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol (2008) 1.89
Self-regulation of Candida albicans population size during GI colonization. PLoS Pathog (2007) 1.85
Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology (2010) 1.83
Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors. J Comb Chem (2006) 1.79
Prevalence of Enterocytozoon bieneusi in swine: an 18-month survey at a slaughterhouse in Massachusetts. Appl Environ Microbiol (2002) 1.78
Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem Biol (2007) 1.78
Genomic survey of the non-cultivatable opportunistic human pathogen, Enterocytozoon bieneusi. PLoS Pathog (2009) 1.73
Cryptosporidium parvum in children with diarrhea in Mulago Hospital, Kampala, Uganda. Am J Trop Med Hyg (2003) 1.64
Respiratory cryptosporidiosis in HIV-seronegative children in Uganda: potential for respiratory transmission. Clin Infect Dis (2010) 1.56
Enterocytozoon bieneusi among children with diarrhea attending Mulago Hospital in Uganda. Am J Trop Med Hyg (2002) 1.50
Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect Immun (2002) 1.49
Cryptosporidiosis in children in Sub-Saharan Africa: a lingering challenge. Clin Infect Dis (2008) 1.46
Piglet models of acute or chronic Clostridium difficile illness. J Infect Dis (2010) 1.38
Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect Immun (2005) 1.38
Mouse relapse model of Clostridium difficile infection. Infect Immun (2011) 1.36
Cryptosporidium hominis: experimental challenge of healthy adults. Am J Trop Med Hyg (2006) 1.35
An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins. J Microbiol Methods (2009) 1.34
Cholesterol-dependent pore formation of Clostridium difficile toxin A. J Biol Chem (2006) 1.32
The reduced genome of the parasitic microsporidian Enterocytozoon bieneusi lacks genes for core carbon metabolism. Genome Biol Evol (2010) 1.30
The shikimate pathway and its branches in apicomplexan parasites. J Infect Dis (2002) 1.25
Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis (2012) 1.25
A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS One (2012) 1.24
Production and characterization of protective human antibodies against Shiga toxin 1. Infect Immun (2002) 1.23
Cellular stability of Rho-GTPases glucosylated by Clostridium difficile toxin B. FEBS Lett (2006) 1.22
Infectivity of a Cryptosporidium parvum isolate of cervine origin for healthy adults and interferon-gamma knockout mice. J Infect Dis (2002) 1.22
A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun (2012) 1.22
Antibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin A. Infect Immun (2009) 1.21
Expression of recombinant Clostridium difficile toxin A using the Bacillus megaterium system. Biochem Biophys Res Commun (2003) 1.21
Identification of genotypically mixed Cryptosporidium parvum populations in humans and calves. Mol Biochem Parasitol (2003) 1.21
The complete receptor-binding domain of Clostridium difficile toxin A is required for endocytosis. Biochem Biophys Res Commun (2003) 1.20
Host S-nitrosylation inhibits clostridial small molecule-activated glucosylating toxins. Nat Med (2011) 1.19
Intracellular neutralization of shiga toxin 2 by an a subunit-specific human monoclonal antibody. Infect Immun (2008) 1.19
Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex. Biochemistry (2008) 1.17
Patterns of genome evolution among the microsporidian parasites Encephalitozoon cuniculi, Antonospora locustae and Enterocytozoon bieneusi. PLoS One (2007) 1.16
A pig model of the human gastrointestinal tract. Gut Microbes (2013) 1.15
Inferences about the global population structures of Cryptosporidium parvum and Cryptosporidium hominis. Appl Environ Microbiol (2008) 1.15
The repetitive oligopeptide sequences modulate cytopathic potency but are not crucial for cellular uptake of Clostridium difficile toxin A. PLoS One (2011) 1.13
Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants. Infect Immun (2003) 1.12
Autoproteolytic cleavage mediates cytotoxicity of Clostridium difficile toxin A. Naunyn Schmiedebergs Arch Pharmacol (2010) 1.12
Experimental evidence for genetic recombination in the opportunistic pathogen Cryptosporidium parvum. Mol Biochem Parasitol (2002) 1.09
Increased adherence and actin pedestal formation by dam-deficient enterohaemorrhagic Escherichia coli O157:H7. Mol Microbiol (2007) 1.09
Rac function is crucial for cell migration but is not required for spreading and focal adhesion formation. J Cell Sci (2013) 1.08
The enterotoxicity of Clostridium difficile toxins. Toxins (Basel) (2010) 1.07
Difference in the cytotoxic effects of toxin B from Clostridium difficile strain VPI 10463 and toxin B from variant Clostridium difficile strain 1470. Infect Immun (2006) 1.07
Application of mutated Clostridium difficile toxin A for determination of glucosyltransferase-dependent effects. Infect Immun (2006) 1.06
Characterization of RAP, a quorum sensing activator of Staphylococcus aureus. FEMS Microbiol Lett (2003) 1.06
A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2. Infect Immun (2013) 1.06
EspFU, a type III-translocated effector of actin assembly, fosters epithelial association and late-stage intestinal colonization by E. coli O157:H7. Cell Microbiol (2007) 1.06
Detection and genotyping of oocysts of Cryptosporidium parvum by real-time PCR and melting curve analysis. J Clin Microbiol (2002) 1.05
Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother (2003) 1.05
The spinal muscular atrophy disease protein SMN is linked to the Rho-kinase pathway via profilin. Hum Mol Genet (2011) 1.04
Characterization of Cryptosporidium meleagridis of human origin passaged through different host species. Infect Immun (2003) 1.02
Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents. Infect Immun (2009) 1.02
Granzyme B binds to target cells mostly by charge and must be added at the same time as perforin to trigger apoptosis. J Immunol (2005) 1.00
Clostridium difficile toxin A-induced apoptosis is p53-independent but depends on glucosylation of Rho GTPases. Apoptosis (2007) 0.99
Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood (2003) 0.99
Development of a Bacillus subtilis-based rotavirus vaccine. Clin Vaccine Immunol (2010) 0.98
A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol (2005) 0.98
Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection. J Infect Dis (2009) 0.98
Production and characterization of monoclonal antibodies against Enterocytozoon bieneusi purified from rhesus macaques. Infect Immun (2005) 0.97
Purification of Enterocytozoon bieneusi from stools and production of specific antibodies. J Clin Microbiol (2005) 0.97
Clostridium difficile toxins A and B directly stimulate human mast cells. Infect Immun (2007) 0.97
Release of TcdA and TcdB from Clostridium difficile cdi 630 is not affected by functional inactivation of the tcdE gene. Microb Pathog (2011) 0.97
Upregulation of the immediate early gene product RhoB by exoenzyme C3 from Clostridium limosum and toxin B from Clostridium difficile. Biochemistry (2007) 0.95
Evidence for mitochondrial-derived alternative oxidase in the apicomplexan parasite Cryptosporidium parvum: a potential anti-microbial agent target. Int J Parasitol (2004) 0.95
Pyknotic cell death induced by Clostridium difficile TcdB: chromatin condensation and nuclear blister are induced independently of the glucosyltransferase activity. Cell Microbiol (2014) 0.94
Entrapment of Rho ADP-ribosylated by Clostridium botulinum C3 exoenzyme in the Rho-guanine nucleotide dissociation inhibitor-1 complex. J Biol Chem (2003) 0.94
The Shigella dysenteriae serotype 1 proteome, profiled in the host intestinal environment, reveals major metabolic modifications and increased expression of invasive proteins. Proteomics (2009) 0.94
A segment of 97 amino acids within the translocation domain of Clostridium difficile toxin B is essential for toxicity. PLoS One (2013) 0.93
Rapid displacement of Cryptosporidium parvum type 1 by type 2 in mixed infections in piglets. Infect Immun (2003) 0.92
Subtype analysis of Cryptosporidium isolates from children in Uganda. J Parasitol (2006) 0.91
Serine-71 phosphorylation of Rac1/Cdc42 diminishes the pathogenic effect of Clostridium difficile toxin A. Cell Microbiol (2009) 0.91
Quantitative tracking of Cryptosporidium infection in cell culture with CFSE. J Parasitol (2006) 0.91
Allele- and tir-independent functions of intimin in diverse animal infection models. Front Microbiol (2012) 0.91
Microsporidiosis and malnutrition in children with persistent diarrhea, Uganda. Emerg Infect Dis (2009) 0.91
Comparison of two label-free global quantitation methods, APEX and 2D gel electrophoresis, applied to the Shigella dysenteriae proteome. Proteome Sci (2009) 0.91
Evaluation of Fab and F(ab')2 fragments and isotype variants of a recombinant human monoclonal antibody against Shiga toxin 2. Infect Immun (2010) 0.91
Enhanced Actin Pedestal Formation by Enterohemorrhagic Escherichia coli O157:H7 Adapted to the Mammalian Host. Front Microbiol (2011) 0.90
Cytotoxicity of Clostridium difficile toxin B does not require cysteine protease-mediated autocleavage and release of the glucosyltransferase domain into the host cell cytosol. Pathog Dis (2013) 0.90
Tegumental phosphodiesterase SmNPP-5 is a virulence factor for schistosomes. Infect Immun (2011) 0.90
Bacillus subtilis: a temperature resistant and needle free delivery system of immunogens. Hum Vaccin Immunother (2012) 0.90
Monoclonal antibodies against Enterocytozoon bieneusi of human origin. Clin Diagn Lab Immunol (2005) 0.90
Killing of rat basophilic leukemia cells by lethal toxin from Clostridium sordellii: critical role of phosphatidylinositide 3'-OH kinase/Akt signaling. Biochemistry (2009) 0.89
Efficacy, heat stability and safety of intranasally administered Bacillus subtilis spore or vegetative cell vaccines expressing tetanus toxin fragment C. Vaccine (2010) 0.89
Cryptosporidium meleagridis: infectivity in healthy adult volunteers. Am J Trop Med Hyg (2011) 0.89
Infection with Cryptosporidium hominis provides incomplete protection of the host against Cryptosporidium parvum. J Infect Dis (2012) 0.89
Serial propagation of the microsporidian Enterocytozoon bieneusi of human origin in immunocompromised rodents. Infect Immun (2006) 0.89
Hyperimmune bovine colostrum for treatment of GI infections: a review and update on Clostridium difficile. Hum Vaccin Immunother (2013) 0.87